In phase 3, randomized, placebo-controlled, PIONEER trials, investigators estimated the data to evaluate the optimal medium-term adalimumab maintenance dosing strategy in moderate-to-severe hidradenitis suppurativa (HS). They randomized the candidates to adalimumab 40 mg every-week (ADAew) (Period A) and then, re-randomized in Period B to ADAew (ADAew/ew), ADA every-other-week (ADAew/eow), or placebo (ADAew/pbo). They observed the HiSCR week-36 rate, 48·1% (ADAew/ew) vs 46·2% (ADAew/eow) and 32·1% (ADAew/pbo) for week-12 HiSCR achievers. They reported better outcomes in partial response after 12 weeks with continued weekly dosing than dose reduction or interruption, with no remarkable differences in safety profile.
Read the full article on British Journal of Dermatology